Chimeric antigen receptor (CAR) T cell therapy has led to impressive clinical responses in patients with hematological malignancies; however, its effectiveness in patients with solid tumors has been limited. While CAR T cells for the treatment of advanced prostate and pancreas cancer, including those targeting prostate stem cell antigen (PSCA), are being clinically evaluated and are anticipated to show bioactivity, their safety and the impact of the immunosuppressive tumor microenvironment (TME) have not been faithfully explored preclinically. Using a novel human PSCA knockin (hPSCA-KI) immunocompetent mouse model, we evaluated the safety and therapeutic efficacy of PSCA-CAR T cells. We demonstrated that cyclophosphamide (Cy) pre-conditioning significantly modified the immunosuppressive TME and was required to uncover the efficacy of PSCA-CAR T cells in metastatic prostate and pancreas cancer models, with no observed toxicities in normal tissues with endogenous expression of PSCA. This combination dampened the immunosuppressive TME, generated pro-inflammatory myeloid and T cell signatures in tumors, and enhanced the recruitment of antigen-presenting cells, as well as endogenous and adoptively transferred T cells, resulting in long-term anti-tumor immunity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261088 | PMC |
| http://dx.doi.org/10.1016/j.ymthe.2021.02.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Better, Faster, Stronger: Accelerating mRNA-Based Immunotherapies With Nanocarriers.
Wiley Interdiscip Rev Nanomed Nanobiotechnol
November 2024
Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal.
Messenger ribonucleic acid (mRNA) therapeutics are attracting attention as promising tools in cancer immunotherapy due to their ability to leverage the in vivo expression of all known protein sequences. Even small amounts of mRNA can have a powerful effect on cancer vaccines by promoting the synthesis of tumor-specific antigens (TSA) or tumor-associated antigens (TAA) by antigen-presenting cells (APC). These antigens are then presented to T cells, eliciting strong antitumor immune stimulation.
View Article and Find Full Text PDFQuantitative pharmacology of dual-targeted bicistronic CAR-T-cell therapy using multiscale mechanistic modeling.
CPT Pharmacometrics Syst Pharmacol
November 2024
Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Despite the initial success of single-targeted chimeric-antigen receptor (CAR) T-cell therapy in hematological malignancies, its long-term effectiveness is often hindered by antigen heterogeneity and escape. As a result, there is a growing interest in cell therapies targeting multiple antigens (≥2). However, the dose-exposure-response relationship and specific factors influencing the pharmacology of dual-targeted CAR-T-cell therapy remain unclear.
View Article and Find Full Text PDFBispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy.
Expert Opin Biol Ther
December 2024
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy and have enhanced the survival of patients with malignant tumors. However, the overall efficacy of ICIs remains unsatisfactory and is faced with two major concerns of resistance development and occurrence of immune-related adverse events (irAEs). Bispecific antibodies (bsAbs) have emerged as promising strategies with unique mechanisms of action to achieve a better efficacy and safety than monoclonal antibodies (mAbs) or even their combination.
View Article and Find Full Text PDFDNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M).
Commun Biol
October 2024
RocRock Biotechnology Co. Ltd, Suzhou, China.
Article Synopsis
- CAR T-cell therapies have been effective for blood cancers but face challenges in treating solid tumors; CAR-macrophages (CAR-M) are being explored as an alternative therapy.*
- CAR-M can be activated and target tumors using tumor-associated antigens, but the mechanisms of their movement and infiltration in tumors are not fully understood.*
- This study uses a 3D tumor spheroid model created from self-assembling nucleic acid nanostructures to evaluate CAR-M's effectiveness, showing better invasion and tumor-killing abilities compared to traditional 2D models.*
Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer.
Mol Ther Oncol
December 2024
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Article Synopsis
- - Pancreatic cancer is a tough-to-treat disease with only a 13% survival rate over five years, and current immunotherapies like CAR T cells aren't very effective for it.
- - Researchers identified Muc16CD as a new target (tumor-associated antigen) that CAR T cells can attack, which is present in pancreatic tumors.
- - Muc16CD-targeted CAR T cells show promise in laboratory models, effectively recognizing pancreatic tumor cells and improving tumor control and survival rates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!